Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

One chemistry tweak made mRNA vaccines dramatically safer and more effective—unlocking new potential for fighting disease.

Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to ...

A fed-batch reaction is harder to design than a batch process because of the need to specify all the variables and quantities.

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Key opportunities in the travel vaccines market include increased demand from heightened post-COVID-19 awareness, ...

Experts hope the research, published Monday in the journal Nature Medicine, may allow for earlier interventions. Other research-related news is on the first pill for postpartum depression, antibiotic ...

Lockheed Martin Corp (NYSE:LMT) is also taking a tumble before the bell, suffering a steep 8% drop after significant one-time ...

Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system ...

While no vision loss was noted, researchers observed slight corneal thickening and decreased endothelial cell count, ...